Skip to main content
. Author manuscript; available in PMC: 2019 Apr 12.
Published in final edited form as: Science. 2018 Sep 6;362(6411):236–239. doi: 10.1126/science.aau5138

Fig. 4. AcrVAs robustly inhibit genome editing by specific CRISPR-Cas12a nucleases in mammalian cells.

Fig. 4.

(A) Overview of the editing reporter assay in human cells. (B) Quantification of genome editing in reporter cell lines stably expressing the indicated CRISPR-Cas12a inhibitors (AcrVAs) or a control (mTagBFP2, mCherry). The scale of each plot is adjusted to compensate for differences in editing efficiency. Error bars indicate standard deviations of triplicates. (C) Biochemical analysis of AcrVA-mediated inhibition in representative samples shown in (B). Editing was assessed by the T7 endonuclease 1 (T7E1) assay.